JP4892335B2 - インターロイキン１５（ｉｌ−１５）に特異的なヒト抗体 - Google Patents

インターロイキン１５（ｉｌ−１５）に特異的なヒト抗体 Download PDF

Info

Publication number: JP4892335B2
Authority: JP; Japan
Prior art keywords: human; antibody; cells; antibodies; sequence
Prior art date: 2003-02-26
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

JP2006502466A

Other languages

English (en)

Japanese (ja)

Other versions

JP2007528348A (ja

Inventor

デウィンケル，ヤン，ヘー．，イェイ．ファン

ダイク，マルクス，アントニーウスファン

ジャニンヌスヒュールマン，

アルナウト，エフ．ヒェリッツェン，

オレ，ディー．，エム．，エスシーバーズゴン，

ヨーンペターセン，

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Genmab AS

Original Assignee

Genmab AS

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-02-26

Filing date

2004-02-25

Publication date

2012-03-07

2003-02-26 Priority claimed from US10/374,932 external-priority patent/US7329405B2/en

2003-03-05 Priority claimed from US10/379,741 external-priority patent/US7247304B2/en

2004-02-25 Application filed by Genmab AS filed Critical Genmab AS

2007-10-11 Publication of JP2007528348A publication Critical patent/JP2007528348A/ja

2012-03-07 Application granted granted Critical

2012-03-07 Publication of JP4892335B2 publication Critical patent/JP4892335B2/ja

2024-02-25 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

241000282414 Homo sapiens Species 0.000 title claims description 342
102000003812 Interleukin-15 Human genes 0.000 title description 216
108090000172 Interleukin-15 Proteins 0.000 title description 216
101001055157 Homo sapiens Interleukin-15 Proteins 0.000 claims description 102
102000056003 human IL15 Human genes 0.000 claims description 102
230000027455 binding Effects 0.000 claims description 73
239000000427 antigen Substances 0.000 claims description 59
108091007433 antigens Proteins 0.000 claims description 59
102000036639 antigens Human genes 0.000 claims description 59
201000004681 Psoriasis Diseases 0.000 claims description 28
239000003814 drug Substances 0.000 claims description 28
238000011282 treatment Methods 0.000 claims description 27
125000003275 alpha amino acid group Chemical group 0.000 claims description 26
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 25
102000004556 Interleukin-15 Receptors Human genes 0.000 claims description 17
108010017535 Interleukin-15 Receptors Proteins 0.000 claims description 17
238000004519 manufacturing process Methods 0.000 claims description 15
229940079593 drug Drugs 0.000 claims description 14
108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 12
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 12
108040002039 interleukin-15 receptor activity proteins Proteins 0.000 claims description 12
102000008616 interleukin-15 receptor activity proteins Human genes 0.000 claims description 12
239000003446 ligand Substances 0.000 claims description 12
-1 brequinal Chemical compound 0.000 claims description 11
229940124597 therapeutic agent Drugs 0.000 claims description 11
MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 10
239000003018 immunosuppressive agent Substances 0.000 claims description 10
239000002988 disease modifying antirheumatic drug Substances 0.000 claims description 8
238000001126 phototherapy Methods 0.000 claims description 7
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 6
GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 claims description 6
WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 claims description 6
102000003814 Interleukin-10 Human genes 0.000 claims description 5
108090000174 Interleukin-10 Proteins 0.000 claims description 5
102000003675 cytokine receptors Human genes 0.000 claims description 5
108010057085 cytokine receptors Proteins 0.000 claims description 5
RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 claims description 5
229960004866 mycophenolate mofetil Drugs 0.000 claims description 5
108010008165 Etanercept Proteins 0.000 claims description 4
VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 claims description 4
108010074328 Interferon-gamma Proteins 0.000 claims description 4
206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims description 4
QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims description 4
239000003246 corticosteroid Substances 0.000 claims description 4
229960001330 hydroxycarbamide Drugs 0.000 claims description 4
230000001506 immunosuppresive effect Effects 0.000 claims description 4
229960003444 immunosuppressant agent Drugs 0.000 claims description 4
230000001861 immunosuppressant effect Effects 0.000 claims description 4
201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims description 4
VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 claims description 4
230000011664 signaling Effects 0.000 claims description 4
NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 claims description 4
108010044091 Globulins Proteins 0.000 claims description 3
102100037850 Interferon gamma Human genes 0.000 claims description 3
108090001005 Interleukin-6 Proteins 0.000 claims description 3
UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 claims description 3
229960004397 cyclophosphamide Drugs 0.000 claims description 3
229960000403 etanercept Drugs 0.000 claims description 3
229960000598 infliximab Drugs 0.000 claims description 3
108040006849 interleukin-2 receptor activity proteins Proteins 0.000 claims description 3
229960000681 leflunomide Drugs 0.000 claims description 3
229960001428 mercaptopurine Drugs 0.000 claims description 3
NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 claims description 3
229960001940 sulfasalazine Drugs 0.000 claims description 3
201000000596 systemic lupus erythematosus Diseases 0.000 claims description 3
229960003087 tioguanine Drugs 0.000 claims description 3
IDINUJSAMVOPCM-UHFFFAOYSA-N 15-Deoxyspergualin Natural products NCCCNCCCCNC(=O)C(O)NC(=O)CCCCCCN=C(N)N IDINUJSAMVOPCM-UHFFFAOYSA-N 0.000 claims description 2
206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 2
102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 2
101150013553 CD40 gene Proteins 0.000 claims description 2
102000006395 Globulins Human genes 0.000 claims description 2
101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 2
101001063392 Homo sapiens Lymphocyte function-associated antigen 3 Proteins 0.000 claims description 2
101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims description 2
101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 2
108090000978 Interleukin-4 Proteins 0.000 claims description 2
108010002586 Interleukin-7 Proteins 0.000 claims description 2
108090001007 Interleukin-8 Proteins 0.000 claims description 2
102100030984 Lymphocyte function-associated antigen 3 Human genes 0.000 claims description 2
HZQDCMWJEBCWBR-UUOKFMHZSA-N Mizoribine Chemical compound OC1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 HZQDCMWJEBCWBR-UUOKFMHZSA-N 0.000 claims description 2
206010034277 Pemphigoid Diseases 0.000 claims description 2
102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims description 2
206010040047 Sepsis Diseases 0.000 claims description 2
102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 2
102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 2
229960002459 alefacept Drugs 0.000 claims description 2
NUZWLKWWNNJHPT-UHFFFAOYSA-N anthralin Chemical compound C1C2=CC=CC(O)=C2C(=O)C2=C1C=CC=C2O NUZWLKWWNNJHPT-UHFFFAOYSA-N 0.000 claims description 2
230000001494 anti-thymocyte effect Effects 0.000 claims description 2
239000003430 antimalarial agent Substances 0.000 claims description 2
208000000594 bullous pemphigoid Diseases 0.000 claims description 2
229960002311 dithranol Drugs 0.000 claims description 2
229960000284 efalizumab Drugs 0.000 claims description 2
230000002124 endocrine Effects 0.000 claims description 2
206010020718 hyperplasia Diseases 0.000 claims description 2
HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 claims description 2
229950000844 mizoribine Drugs 0.000 claims description 2
229960000951 mycophenolic acid Drugs 0.000 claims description 2
HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 claims description 2
BLUYEPLOXLPVCJ-INIZCTEOSA-N n-[(1s)-2-[4-(3-aminopropylamino)butylamino]-1-hydroxyethyl]-7-(diaminomethylideneamino)heptanamide Chemical compound NCCCNCCCCNC[C@H](O)NC(=O)CCCCCCNC(N)=N BLUYEPLOXLPVCJ-INIZCTEOSA-N 0.000 claims description 2
ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims description 2
231100000241 scar Toxicity 0.000 claims description 2
QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims description 2
229960002930 sirolimus Drugs 0.000 claims description 2
208000035475 disorder Diseases 0.000 claims 3
229960001967 tacrolimus Drugs 0.000 claims 2
QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 claims 2
JAJIPIAHCFBEPI-UHFFFAOYSA-N 9,10-dioxoanthracene-1-sulfonic acid Chemical compound O=C1C2=CC=CC=C2C(=O)C2=C1C=CC=C2S(=O)(=O)O JAJIPIAHCFBEPI-UHFFFAOYSA-N 0.000 claims 1
206010059245 Angiopathy Diseases 0.000 claims 1
229940123907 Disease modifying antirheumatic drug Drugs 0.000 claims 1
108010002616 Interleukin-5 Proteins 0.000 claims 1
208000019693 Lung disease Diseases 0.000 claims 1
208000012902 Nervous system disease Diseases 0.000 claims 1
208000018631 connective tissue disease Diseases 0.000 claims 1
208000018706 hematopoietic system disease Diseases 0.000 claims 1
230000002390 hyperplastic effect Effects 0.000 claims 1
208000019423 liver disease Diseases 0.000 claims 1
208000019553 vascular disease Diseases 0.000 claims 1
210000004027 cell Anatomy 0.000 description 161
108090000623 proteins and genes Proteins 0.000 description 95
108700019146 Transgenes Proteins 0.000 description 81
241001465754 Metazoa Species 0.000 description 62
238000000034 method Methods 0.000 description 58
230000009261 transgenic effect Effects 0.000 description 56
239000000203 mixture Substances 0.000 description 53
150000001875 compounds Chemical class 0.000 description 46
241000699670 Mus sp. Species 0.000 description 45
108010047041 Complementarity Determining Regions Proteins 0.000 description 43
241000699666 Mus <mouse, genus> Species 0.000 description 43
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 39
239000002953 phosphate buffered saline Substances 0.000 description 39
239000012634 fragment Substances 0.000 description 38
210000004408 hybridoma Anatomy 0.000 description 37
210000004602 germ cell Anatomy 0.000 description 35
108060003951 Immunoglobulin Proteins 0.000 description 34
102000018358 immunoglobulin Human genes 0.000 description 34
210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 34
230000035755 proliferation Effects 0.000 description 30
238000002965 ELISA Methods 0.000 description 29
239000013598 vector Substances 0.000 description 29
108020004414 DNA Proteins 0.000 description 27
206010039073 rheumatoid arthritis Diseases 0.000 description 27
238000011830 transgenic mouse model Methods 0.000 description 27
230000006433 tumor necrosis factor production Effects 0.000 description 27
150000007523 nucleic acids Chemical class 0.000 description 25
239000013612 plasmid Substances 0.000 description 25
238000010186 staining Methods 0.000 description 25
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 24
108010036949 Cyclosporine Proteins 0.000 description 24
230000005856 abnormality Effects 0.000 description 24
210000003719 b-lymphocyte Anatomy 0.000 description 24
230000000694 effects Effects 0.000 description 24
230000001404 mediated effect Effects 0.000 description 24
230000001225 therapeutic effect Effects 0.000 description 24
210000001519 tissue Anatomy 0.000 description 24
102000039446 nucleic acids Human genes 0.000 description 23
108020004707 nucleic acids Proteins 0.000 description 23
239000002773 nucleotide Substances 0.000 description 23
125000003729 nucleotide group Chemical group 0.000 description 23
238000002360 preparation method Methods 0.000 description 23
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 22
201000010099 disease Diseases 0.000 description 22
239000000243 solution Substances 0.000 description 22
230000014509 gene expression Effects 0.000 description 21
108010002350 Interleukin-2 Proteins 0.000 description 20
102000000588 Interleukin-2 Human genes 0.000 description 20
229960001265 ciclosporin Drugs 0.000 description 20
210000002966 serum Anatomy 0.000 description 20
230000035772 mutation Effects 0.000 description 18
101100506090 Caenorhabditis elegans hil-2 gene Proteins 0.000 description 17
235000018102 proteins Nutrition 0.000 description 17
102000004169 proteins and genes Human genes 0.000 description 17
238000005516 engineering process Methods 0.000 description 16
230000005764 inhibitory process Effects 0.000 description 16
210000002510 keratinocyte Anatomy 0.000 description 16
102000005962 receptors Human genes 0.000 description 16
108020003175 receptors Proteins 0.000 description 16
230000006798 recombination Effects 0.000 description 16
238000005215 recombination Methods 0.000 description 16
241000894007 species Species 0.000 description 16
238000005406 washing Methods 0.000 description 16
229930105110 Cyclosporin A Natural products 0.000 description 15
239000003795 chemical substances by application Substances 0.000 description 15
210000001616 monocyte Anatomy 0.000 description 15
241000699660 Mus musculus Species 0.000 description 14
229960002685 biotin Drugs 0.000 description 14
239000011616 biotin Substances 0.000 description 14
230000002401 inhibitory effect Effects 0.000 description 14
108091028043 Nucleic acid sequence Proteins 0.000 description 13
210000001744 T-lymphocyte Anatomy 0.000 description 13
239000013604 expression vector Substances 0.000 description 13
229910052739 hydrogen Inorganic materials 0.000 description 13
238000002347 injection Methods 0.000 description 13
239000007924 injection Substances 0.000 description 13
239000008194 pharmaceutical composition Substances 0.000 description 13
102000004127 Cytokines Human genes 0.000 description 12
108090000695 Cytokines Proteins 0.000 description 12
230000006872 improvement Effects 0.000 description 12
108090000765 processed proteins & peptides Proteins 0.000 description 12
230000008707 rearrangement Effects 0.000 description 12
239000000523 sample Substances 0.000 description 12
108091003079 Bovine Serum Albumin Proteins 0.000 description 11
235000001014 amino acid Nutrition 0.000 description 11
235000020958 biotin Nutrition 0.000 description 11
239000000872 buffer Substances 0.000 description 11
238000010790 dilution Methods 0.000 description 11
239000012895 dilution Substances 0.000 description 11
238000010494 dissociation reaction Methods 0.000 description 11
230000005593 dissociations Effects 0.000 description 11
238000011534 incubation Methods 0.000 description 11
229920001184 polypeptide Polymers 0.000 description 11
102000004196 processed proteins & peptides Human genes 0.000 description 11
238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 11
206010069754 Acquired gene mutation Diseases 0.000 description 10
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 10
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 10
238000011579 SCID mouse model Methods 0.000 description 10
239000012491 analyte Substances 0.000 description 10
238000004458 analytical method Methods 0.000 description 10
238000001574 biopsy Methods 0.000 description 10
238000010367 cloning Methods 0.000 description 10
238000012217 deletion Methods 0.000 description 10
230000037430 deletion Effects 0.000 description 10
239000002552 dosage form Substances 0.000 description 10
230000006870 function Effects 0.000 description 10
230000004927 fusion Effects 0.000 description 10
238000000338 in vitro Methods 0.000 description 10
230000003993 interaction Effects 0.000 description 10
239000002502 liposome Substances 0.000 description 10
230000004048 modification Effects 0.000 description 10
238000012986 modification Methods 0.000 description 10
230000000770 proinflammatory effect Effects 0.000 description 10
230000037439 somatic mutation Effects 0.000 description 10
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 10
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
206010028980 Neoplasm Diseases 0.000 description 9
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 9
229940024606 amino acid Drugs 0.000 description 9
125000000539 amino acid group Chemical group 0.000 description 9
150000001413 amino acids Chemical class 0.000 description 9
UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 9
238000009472 formulation Methods 0.000 description 9
238000001727 in vivo Methods 0.000 description 9
230000002757 inflammatory effect Effects 0.000 description 9
210000001165 lymph node Anatomy 0.000 description 9
210000002540 macrophage Anatomy 0.000 description 9
229960000485 methotrexate Drugs 0.000 description 9
150000003839 salts Chemical class 0.000 description 9
230000000638 stimulation Effects 0.000 description 9
239000000126 substance Substances 0.000 description 9
230000008685 targeting Effects 0.000 description 9
WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 8
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 8
239000004480 active ingredient Substances 0.000 description 8
229940127089 cytotoxic agent Drugs 0.000 description 8
238000002474 experimental method Methods 0.000 description 8
238000001943 fluorescence-activated cell sorting Methods 0.000 description 8
230000003053 immunization Effects 0.000 description 8
238000012360 testing method Methods 0.000 description 8
ZTOJFFHGPLIVKC-YAFCTCPESA-N (2e)-3-ethyl-2-[(z)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound S\1C2=CC(S(O)(=O)=O)=CC=C2N(CC)C/1=N/N=C1/SC2=CC(S(O)(=O)=O)=CC=C2N1CC ZTOJFFHGPLIVKC-YAFCTCPESA-N 0.000 description 7
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 7
241000287828 Gallus gallus Species 0.000 description 7
108091034117 Oligonucleotide Proteins 0.000 description 7
206010035226 Plasma cell myeloma Diseases 0.000 description 7
229920001213 Polysorbate 20 Polymers 0.000 description 7
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
101150117115 V gene Proteins 0.000 description 7
239000002246 antineoplastic agent Substances 0.000 description 7
210000004369 blood Anatomy 0.000 description 7
239000008280 blood Substances 0.000 description 7
235000013330 chicken meat Nutrition 0.000 description 7
230000000875 corresponding effect Effects 0.000 description 7
231100000599 cytotoxic agent Toxicity 0.000 description 7
231100000673 dose–response relationship Toxicity 0.000 description 7
239000003937 drug carrier Substances 0.000 description 7
238000012377 drug delivery Methods 0.000 description 7
238000000684 flow cytometry Methods 0.000 description 7
238000002649 immunization Methods 0.000 description 7
230000004054 inflammatory process Effects 0.000 description 7
239000002609 medium Substances 0.000 description 7
210000004940 nucleus Anatomy 0.000 description 7
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 7
210000003491 skin Anatomy 0.000 description 7
230000009870 specific binding Effects 0.000 description 7
210000005222 synovial tissue Anatomy 0.000 description 7
239000003981 vehicle Substances 0.000 description 7
108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
108700005091 Immunoglobulin Genes Proteins 0.000 description 6
206010061218 Inflammation Diseases 0.000 description 6
238000012408 PCR amplification Methods 0.000 description 6
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 6
238000010521 absorption reaction Methods 0.000 description 6
239000002253 acid Substances 0.000 description 6
238000007792 addition Methods 0.000 description 6
239000002671 adjuvant Substances 0.000 description 6
230000033115 angiogenesis Effects 0.000 description 6
229940121363 anti-inflammatory agent Drugs 0.000 description 6
239000002260 anti-inflammatory agent Substances 0.000 description 6
229940098773 bovine serum albumin Drugs 0.000 description 6
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 6
229930182912 cyclosporin Natural products 0.000 description 6
239000006185 dispersion Substances 0.000 description 6
230000012010 growth Effects 0.000 description 6
229940125721 immunosuppressive agent Drugs 0.000 description 6
238000010348 incorporation Methods 0.000 description 6
238000001802 infusion Methods 0.000 description 6
201000000050 myeloid neoplasm Diseases 0.000 description 6
229920001223 polyethylene glycol Polymers 0.000 description 6
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 6
239000000047 product Substances 0.000 description 6
230000001185 psoriatic effect Effects 0.000 description 6
230000001105 regulatory effect Effects 0.000 description 6
210000000952 spleen Anatomy 0.000 description 6
239000000758 substrate Substances 0.000 description 6
208000024891 symptom Diseases 0.000 description 6
238000002054 transplantation Methods 0.000 description 6
208000035473 Communicable disease Diseases 0.000 description 5
101710112752 Cytotoxin Proteins 0.000 description 5
208000009329 Graft vs Host Disease Diseases 0.000 description 5
108010001336 Horseradish Peroxidase Proteins 0.000 description 5
238000012450 HuMAb Mouse Methods 0.000 description 5
229930182555 Penicillin Natural products 0.000 description 5
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 5
239000002202 Polyethylene glycol Substances 0.000 description 5
238000002105 Southern blotting Methods 0.000 description 5
230000006052 T cell proliferation Effects 0.000 description 5
206010052779 Transplant rejections Diseases 0.000 description 5
206010003246 arthritis Diseases 0.000 description 5
230000000903 blocking effect Effects 0.000 description 5
201000011510 cancer Diseases 0.000 description 5
239000003153 chemical reaction reagent Substances 0.000 description 5
239000002299 complementary DNA Substances 0.000 description 5
230000008878 coupling Effects 0.000 description 5
238000010168 coupling process Methods 0.000 description 5
238000005859 coupling reaction Methods 0.000 description 5
239000012228 culture supernatant Substances 0.000 description 5
239000002619 cytotoxin Substances 0.000 description 5
239000003623 enhancer Substances 0.000 description 5
238000002744 homologous recombination Methods 0.000 description 5
230000006801 homologous recombination Effects 0.000 description 5
238000009396 hybridization Methods 0.000 description 5
229940072221 immunoglobulins Drugs 0.000 description 5
238000005304 joining Methods 0.000 description 5
238000012423 maintenance Methods 0.000 description 5
230000007246 mechanism Effects 0.000 description 5
229940049954 penicillin Drugs 0.000 description 5
230000002829 reductive effect Effects 0.000 description 5
230000010076 replication Effects 0.000 description 5
229960005322 streptomycin Drugs 0.000 description 5
235000000346 sugar Nutrition 0.000 description 5
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 4
108700028369 Alleles Proteins 0.000 description 4
208000023275 Autoimmune disease Diseases 0.000 description 4
108091026890 Coding region Proteins 0.000 description 4
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
102000004190 Enzymes Human genes 0.000 description 4
108090000790 Enzymes Proteins 0.000 description 4
101150008942 J gene Proteins 0.000 description 4
229930182816 L-glutamine Natural products 0.000 description 4
108010021466 Mutant Proteins Proteins 0.000 description 4
102000008300 Mutant Proteins Human genes 0.000 description 4
239000012980 RPMI-1640 medium Substances 0.000 description 4
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 4
150000007513 acids Chemical class 0.000 description 4
229960005339 acitretin Drugs 0.000 description 4
RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 4
IHUNBGSDBOWDMA-AQFIFDHZSA-N all-trans-acitretin Chemical compound COC1=CC(C)=C(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)C(C)=C1C IHUNBGSDBOWDMA-AQFIFDHZSA-N 0.000 description 4
238000003556 assay Methods 0.000 description 4
230000004071 biological effect Effects 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
238000006243 chemical reaction Methods 0.000 description 4
210000000349 chromosome Anatomy 0.000 description 4
238000000576 coating method Methods 0.000 description 4
238000001514 detection method Methods 0.000 description 4
230000029087 digestion Effects 0.000 description 4
230000013595 glycosylation Effects 0.000 description 4
238000006206 glycosylation reaction Methods 0.000 description 4
208000024908 graft versus host disease Diseases 0.000 description 4
230000028993 immune response Effects 0.000 description 4
208000027866 inflammatory disease Diseases 0.000 description 4
239000007951 isotonicity adjuster Substances 0.000 description 4
239000000787 lecithin Substances 0.000 description 4
229940067606 lecithin Drugs 0.000 description 4
235000010445 lecithin Nutrition 0.000 description 4
230000000670 limiting effect Effects 0.000 description 4
239000012528 membrane Substances 0.000 description 4
210000005087 mononuclear cell Anatomy 0.000 description 4
238000002703 mutagenesis Methods 0.000 description 4
231100000350 mutagenesis Toxicity 0.000 description 4
238000011275 oncology therapy Methods 0.000 description 4
239000012188 paraffin wax Substances 0.000 description 4
230000036961 partial effect Effects 0.000 description 4
102000013415 peroxidase activity proteins Human genes 0.000 description 4
108040007629 peroxidase activity proteins Proteins 0.000 description 4
239000000843 powder Substances 0.000 description 4
XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 4
229960004618 prednisone Drugs 0.000 description 4
238000011160 research Methods 0.000 description 4
238000012163 sequencing technique Methods 0.000 description 4
238000013207 serial dilution Methods 0.000 description 4
239000011780 sodium chloride Substances 0.000 description 4
230000007863 steatosis Effects 0.000 description 4
231100000240 steatosis hepatitis Toxicity 0.000 description 4
210000000434 stratum corneum Anatomy 0.000 description 4
239000008399 tap water Substances 0.000 description 4
235000020679 tap water Nutrition 0.000 description 4
238000002560 therapeutic procedure Methods 0.000 description 4
238000013519 translation Methods 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 3
AYXZIZMZXAORLO-UFLZEWODSA-N 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoic acid;1-hydroxypyrrolidine-2,5-dione Chemical compound ON1C(=O)CCC1=O.N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 AYXZIZMZXAORLO-UFLZEWODSA-N 0.000 description 3
STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
108010006654 Bleomycin Proteins 0.000 description 3
101000583080 Bunodosoma granuliferum Delta-actitoxin-Bgr2a Proteins 0.000 description 3
DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 3
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
108010092160 Dactinomycin Proteins 0.000 description 3
108010010803 Gelatin Proteins 0.000 description 3
102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 3
101100297421 Homarus americanus phc-2 gene Proteins 0.000 description 3
241000282412 Homo Species 0.000 description 3
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 3
HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 3
108010067060 Immunoglobulin Variable Region Proteins 0.000 description 3
102000017727 Immunoglobulin Variable Region Human genes 0.000 description 3
208000022559 Inflammatory bowel disease Diseases 0.000 description 3
NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 3
108010051791 Nuclear Antigens Proteins 0.000 description 3
102000019040 Nuclear Antigens Human genes 0.000 description 3
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
240000004808 Saccharomyces cerevisiae Species 0.000 description 3
230000004913 activation Effects 0.000 description 3
230000007720 allelic exclusion Effects 0.000 description 3
229910000147 aluminium phosphate Inorganic materials 0.000 description 3
239000003242 anti bacterial agent Substances 0.000 description 3
239000003963 antioxidant agent Substances 0.000 description 3
235000006708 antioxidants Nutrition 0.000 description 3
238000013459 approach Methods 0.000 description 3
208000010668 atopic eczema Diseases 0.000 description 3
WZSDNEJJUSYNSG-UHFFFAOYSA-N azocan-1-yl-(3,4,5-trimethoxyphenyl)methanone Chemical compound COC1=C(OC)C(OC)=CC(C(=O)N2CCCCCCC2)=C1 WZSDNEJJUSYNSG-UHFFFAOYSA-N 0.000 description 3
230000001580 bacterial effect Effects 0.000 description 3
239000002585 base Substances 0.000 description 3
238000007413 biotinylation Methods 0.000 description 3
230000006287 biotinylation Effects 0.000 description 3
230000008499 blood brain barrier function Effects 0.000 description 3
210000001218 blood-brain barrier Anatomy 0.000 description 3
229910002091 carbon monoxide Inorganic materials 0.000 description 3
239000000969 carrier Substances 0.000 description 3
230000001413 cellular effect Effects 0.000 description 3
238000012512 characterization method Methods 0.000 description 3
230000035605 chemotaxis Effects 0.000 description 3
210000004978 chinese hamster ovary cell Anatomy 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
239000011248 coating agent Substances 0.000 description 3
229960001334 corticosteroids Drugs 0.000 description 3
239000002254 cytotoxic agent Substances 0.000 description 3
STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 3
230000002950 deficient Effects 0.000 description 3
230000001419 dependent effect Effects 0.000 description 3
210000004207 dermis Anatomy 0.000 description 3
238000000502 dialysis Methods 0.000 description 3
239000002612 dispersion medium Substances 0.000 description 3
239000012894 fetal calf serum Substances 0.000 description 3
239000012530 fluid Substances 0.000 description 3
239000000499 gel Substances 0.000 description 3
229920000159 gelatin Polymers 0.000 description 3
239000008273 gelatin Substances 0.000 description 3
235000019322 gelatine Nutrition 0.000 description 3
235000011852 gelatine desserts Nutrition 0.000 description 3
229940127121 immunoconjugate Drugs 0.000 description 3
230000002163 immunogen Effects 0.000 description 3
239000002596 immunotoxin Substances 0.000 description 3
239000007943 implant Substances 0.000 description 3
239000004615 ingredient Substances 0.000 description 3
238000003780 insertion Methods 0.000 description 3
230000037431 insertion Effects 0.000 description 3
238000007918 intramuscular administration Methods 0.000 description 3
238000007912 intraperitoneal administration Methods 0.000 description 3
238000001990 intravenous administration Methods 0.000 description 3
230000003780 keratinization Effects 0.000 description 3
210000000265 leukocyte Anatomy 0.000 description 3
239000000463 material Substances 0.000 description 3
239000011159 matrix material Substances 0.000 description 3
210000004379 membrane Anatomy 0.000 description 3
201000005962 mycosis fungoides Diseases 0.000 description 3
231100000252 nontoxic Toxicity 0.000 description 3
230000003000 nontoxic effect Effects 0.000 description 3
239000002245 particle Substances 0.000 description 3
210000005259 peripheral blood Anatomy 0.000 description 3
239000011886 peripheral blood Substances 0.000 description 3
239000012071 phase Substances 0.000 description 3
239000000902 placebo Substances 0.000 description 3
229940068196 placebo Drugs 0.000 description 3
230000008488 polyadenylation Effects 0.000 description 3
229920005862 polyol Polymers 0.000 description 3
150000003077 polyols Chemical class 0.000 description 3
230000002265 prevention Effects 0.000 description 3
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
230000008569 process Effects 0.000 description 3
238000000746 purification Methods 0.000 description 3
238000001959 radiotherapy Methods 0.000 description 3
230000009257 reactivity Effects 0.000 description 3
238000003259 recombinant expression Methods 0.000 description 3
238000010188 recombinant method Methods 0.000 description 3
230000004044 response Effects 0.000 description 3
238000012216 screening Methods 0.000 description 3
230000019491 signal transduction Effects 0.000 description 3
239000002904 solvent Substances 0.000 description 3
239000000600 sorbitol Substances 0.000 description 3
210000004988 splenocyte Anatomy 0.000 description 3
230000003637 steroidlike Effects 0.000 description 3
238000007920 subcutaneous administration Methods 0.000 description 3
150000008163 sugars Chemical class 0.000 description 3
GPTONYMQFTZPKC-UHFFFAOYSA-N sulfamethoxydiazine Chemical compound N1=CC(OC)=CN=C1NS(=O)(=O)C1=CC=C(N)C=C1 GPTONYMQFTZPKC-UHFFFAOYSA-N 0.000 description 3
239000004094 surface-active agent Substances 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
230000000699 topical effect Effects 0.000 description 3
IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
IPVFGAYTKQKGBM-BYPJNBLXSA-N 1-[(2r,3s,4r,5r)-3-fluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidine-2,4-dione Chemical compound F[C@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 IPVFGAYTKQKGBM-BYPJNBLXSA-N 0.000 description 2
OXEUETBFKVCRNP-UHFFFAOYSA-N 9-ethyl-3-carbazolamine Chemical compound NC1=CC=C2N(CC)C3=CC=CC=C3C2=C1 OXEUETBFKVCRNP-UHFFFAOYSA-N 0.000 description 2
206010000234 Abortion spontaneous Diseases 0.000 description 2
102000002260 Alkaline Phosphatase Human genes 0.000 description 2
108020004774 Alkaline Phosphatase Proteins 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
239000004322 Butylated hydroxytoluene Substances 0.000 description 2
NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
206010053567 Coagulopathies Diseases 0.000 description 2
108091033380 Coding strand Proteins 0.000 description 2
206010009900 Colitis ulcerative Diseases 0.000 description 2
108010062580 Concanavalin A Proteins 0.000 description 2
101150097493 D gene Proteins 0.000 description 2
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
102000053602 DNA Human genes 0.000 description 2
206010012442 Dermatitis contact Diseases 0.000 description 2
241000588724 Escherichia coli Species 0.000 description 2
PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 2
229920001917 Ficoll Polymers 0.000 description 2
241000233866 Fungi Species 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
102000003886 Glycoproteins Human genes 0.000 description 2
108090000288 Glycoproteins Proteins 0.000 description 2
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
241000725303 Human immunodeficiency virus Species 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 2
108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 2
108010065825 Immunoglobulin Light Chains Proteins 0.000 description 2
102000051628 Interleukin-1 receptor antagonist Human genes 0.000 description 2
108700021006 Interleukin-1 receptor antagonist Proteins 0.000 description 2
102000004889 Interleukin-6 Human genes 0.000 description 2
208000003456 Juvenile Arthritis Diseases 0.000 description 2
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
208000006404 Large Granular Lymphocytic Leukemia Diseases 0.000 description 2
GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
229930195725 Mannitol Natural products 0.000 description 2
BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 description 2
108091005461 Nucleic proteins Chemical group 0.000 description 2
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
108020004511 Recombinant DNA Proteins 0.000 description 2
PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
230000006044 T cell activation Effects 0.000 description 2
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
239000004473 Threonine Substances 0.000 description 2
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
VGQOVCHZGQWAOI-UHFFFAOYSA-N UNPD55612 Natural products N1C(O)C2CC(C=CC(N)=O)=CN2C(=O)C2=CC=C(C)C(O)=C12 VGQOVCHZGQWAOI-UHFFFAOYSA-N 0.000 description 2
201000006704 Ulcerative Colitis Diseases 0.000 description 2
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 2
241000700605 Viruses Species 0.000 description 2
206010052428 Wound Diseases 0.000 description 2
208000027418 Wounds and injury Diseases 0.000 description 2
RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 2
230000009471 action Effects 0.000 description 2
230000001154 acute effect Effects 0.000 description 2
230000009824 affinity maturation Effects 0.000 description 2
239000011543 agarose gel Substances 0.000 description 2
230000000172 allergic effect Effects 0.000 description 2
VGQOVCHZGQWAOI-HYUHUPJXSA-N anthramycin Chemical compound N1[C@@H](O)[C@@H]2CC(\C=C\C(N)=O)=CN2C(=O)C2=CC=C(C)C(O)=C12 VGQOVCHZGQWAOI-HYUHUPJXSA-N 0.000 description 2
230000000844 anti-bacterial effect Effects 0.000 description 2
230000009830 antibody antigen interaction Effects 0.000 description 2
230000005875 antibody response Effects 0.000 description 2
239000003429 antifungal agent Substances 0.000 description 2
229940121375 antifungal agent Drugs 0.000 description 2
230000000890 antigenic effect Effects 0.000 description 2
230000002917 arthritic effect Effects 0.000 description 2
210000001106 artificial yeast chromosome Anatomy 0.000 description 2
208000006673 asthma Diseases 0.000 description 2
229960002170 azathioprine Drugs 0.000 description 2
LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 2
230000008901 benefit Effects 0.000 description 2
230000005540 biological transmission Effects 0.000 description 2
210000002459 blastocyst Anatomy 0.000 description 2
229960001561 bleomycin Drugs 0.000 description 2
OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 2
235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
229940095259 butylated hydroxytoluene Drugs 0.000 description 2
AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
LWQQLNNNIPYSNX-UROSTWAQSA-N calcipotriol Chemical compound C1([C@H](O)/C=C/[C@@H](C)[C@@H]2[C@]3(CCCC(/[C@@H]3CC2)=C\C=C\2C([C@@H](O)C[C@H](O)C/2)=C)C)CC1 LWQQLNNNIPYSNX-UROSTWAQSA-N 0.000 description 2
229960002882 calcipotriol Drugs 0.000 description 2
229960005243 carmustine Drugs 0.000 description 2
239000012876 carrier material Substances 0.000 description 2
RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 2
238000004113 cell culture Methods 0.000 description 2
239000006285 cell suspension Substances 0.000 description 2
230000008859 change Effects 0.000 description 2
JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 2
OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
208000019069 chronic childhood arthritis Diseases 0.000 description 2
230000001684 chronic effect Effects 0.000 description 2
229960004316 cisplatin Drugs 0.000 description 2
239000007979 citrate buffer Substances 0.000 description 2
239000013599 cloning vector Substances 0.000 description 2
230000035602 clotting Effects 0.000 description 2
238000002648 combination therapy Methods 0.000 description 2
230000000295 complement effect Effects 0.000 description 2
230000009918 complex formation Effects 0.000 description 2
208000010247 contact dermatitis Diseases 0.000 description 2
238000013270 controlled release Methods 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
239000006071 cream Substances 0.000 description 2
238000012258 culturing Methods 0.000 description 2
230000001472 cytotoxic effect Effects 0.000 description 2
229960000640 dactinomycin Drugs 0.000 description 2
230000006378 damage Effects 0.000 description 2
229960000975 daunorubicin Drugs 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
230000001934 delay Effects 0.000 description 2
210000004443 dendritic cell Anatomy 0.000 description 2
238000000432 density-gradient centrifugation Methods 0.000 description 2
238000013461 design Methods 0.000 description 2
238000011161 development Methods 0.000 description 2
230000018109 developmental process Effects 0.000 description 2
DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 2
HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 2
UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
229960004679 doxorubicin Drugs 0.000 description 2
238000004520 electroporation Methods 0.000 description 2
230000008030 elimination Effects 0.000 description 2
238000003379 elimination reaction Methods 0.000 description 2
210000001671 embryonic stem cell Anatomy 0.000 description 2
210000002257 embryonic structure Anatomy 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
210000000981 epithelium Anatomy 0.000 description 2
239000012091 fetal bovine serum Substances 0.000 description 2
210000002950 fibroblast Anatomy 0.000 description 2
238000000799 fluorescence microscopy Methods 0.000 description 2
OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
238000004108 freeze drying Methods 0.000 description 2
239000003102 growth factor Substances 0.000 description 2
230000035876 healing Effects 0.000 description 2
229960002897 heparin Drugs 0.000 description 2
229920000669 heparin Polymers 0.000 description 2
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 description 2
210000000987 immune system Anatomy 0.000 description 2
230000036039 immunity Effects 0.000 description 2
238000003365 immunocytochemistry Methods 0.000 description 2
230000002637 immunotoxin Effects 0.000 description 2
229940051026 immunotoxin Drugs 0.000 description 2
231100000608 immunotoxin Toxicity 0.000 description 2
230000002779 inactivation Effects 0.000 description 2
230000006698 induction Effects 0.000 description 2
230000008595 infiltration Effects 0.000 description 2
238000001764 infiltration Methods 0.000 description 2
230000000977 initiatory effect Effects 0.000 description 2
239000007972 injectable composition Substances 0.000 description 2
210000002490 intestinal epithelial cell Anatomy 0.000 description 2
238000007913 intrathecal administration Methods 0.000 description 2
238000002955 isolation Methods 0.000 description 2
229960000310 isoleucine Drugs 0.000 description 2
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
210000001503 joint Anatomy 0.000 description 2
229930027917 kanamycin Natural products 0.000 description 2
SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
229960000318 kanamycin Drugs 0.000 description 2
229930182823 kanamycin A Natural products 0.000 description 2
DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 2
239000007788 liquid Substances 0.000 description 2
239000000594 mannitol Substances 0.000 description 2
235000010355 mannitol Nutrition 0.000 description 2
244000005700 microbiome Species 0.000 description 2
CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 2
229960004857 mitomycin Drugs 0.000 description 2
229940090008 naprosyn Drugs 0.000 description 2
CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 2
229940063121 neoral Drugs 0.000 description 2
239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
230000003204 osmotic effect Effects 0.000 description 2
230000002018 overexpression Effects 0.000 description 2
OFPXSFXSNFPTHF-UHFFFAOYSA-N oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
239000006072 paste Substances 0.000 description 2
230000007170 pathology Effects 0.000 description 2
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
239000008363 phosphate buffer Substances 0.000 description 2
229960003171 plicamycin Drugs 0.000 description 2
239000013641 positive control Substances 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
229960004919 procaine Drugs 0.000 description 2
MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 2
230000000750 progressive effect Effects 0.000 description 2
230000002035 prolonged effect Effects 0.000 description 2
AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical compound C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 description 2
RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
230000000306 recurrent effect Effects 0.000 description 2
229940063122 sandimmune Drugs 0.000 description 2
201000000306 sarcoidosis Diseases 0.000 description 2
239000006152 selective media Substances 0.000 description 2
239000007974 sodium acetate buffer Substances 0.000 description 2
DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
210000001082 somatic cell Anatomy 0.000 description 2
230000000392 somatic effect Effects 0.000 description 2
230000003393 splenic effect Effects 0.000 description 2
208000000995 spontaneous abortion Diseases 0.000 description 2
239000007921 spray Substances 0.000 description 2
238000010561 standard procedure Methods 0.000 description 2
238000003860 storage Methods 0.000 description 2
238000010254 subcutaneous injection Methods 0.000 description 2
239000007929 subcutaneous injection Substances 0.000 description 2
238000006467 substitution reaction Methods 0.000 description 2
150000005846 sugar alcohols Polymers 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
239000002344 surface layer Substances 0.000 description 2
230000004083 survival effect Effects 0.000 description 2
208000001608 teratocarcinoma Diseases 0.000 description 2
230000004797 therapeutic response Effects 0.000 description 2
231100000331 toxic Toxicity 0.000 description 2
230000002588 toxic effect Effects 0.000 description 2
239000003053 toxin Substances 0.000 description 2
231100000765 toxin Toxicity 0.000 description 2
108700012359 toxins Proteins 0.000 description 2
238000013518 transcription Methods 0.000 description 2
230000035897 transcription Effects 0.000 description 2
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
238000011144 upstream manufacturing Methods 0.000 description 2
239000004474 valine Substances 0.000 description 2
229960003048 vinblastine Drugs 0.000 description 2
JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 2
239000013603 viral vector Substances 0.000 description 2
230000003612 virological effect Effects 0.000 description 2
QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 description 1
HMLGSIZOMSVISS-ONJSNURVSA-N (7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2,2-dimethylpropanoyloxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2C(=C(C=C)CSC21)C(O)=O)=O)C(=O)\C(=N/OCOC(=O)C(C)(C)C)C1=CSC(N)=N1 HMLGSIZOMSVISS-ONJSNURVSA-N 0.000 description 1
MWWSFMDVAYGXBV-MYPASOLCSA-N (7r,9s)-7-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydrochloride Chemical compound Cl.O([C@@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-MYPASOLCSA-N 0.000 description 1
FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
GVJHHUAWPYXKBD-IEOSBIPESA-N (R)-alpha-Tocopherol Natural products OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
NNYBQONXHNTVIJ-QGZVFWFLSA-N (R)-etodolac Chemical compound C1CO[C@](CC)(CC(O)=O)C2=C1C(C=CC=C1CC)=C1N2 NNYBQONXHNTVIJ-QGZVFWFLSA-N 0.000 description 1
NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
108020005345 3' Untranslated Regions Proteins 0.000 description 1
WUIABRMSWOKTOF-OYALTWQYSA-N 3-[[2-[2-[2-[[(2s,3r)-2-[[(2s,3s,4r)-4-[[(2s,3r)-2-[[6-amino-2-[(1s)-3-amino-1-[[(2s)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[(2r,3s,4s,5s,6s)-3-[(2r,3s,4s,5r,6r)-4-carbamoyloxy-3,5-dihydroxy-6-(hydroxymethyl)ox Chemical compound OS([O-])(=O)=O.N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1NC=NC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C WUIABRMSWOKTOF-OYALTWQYSA-N 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
VXGRJERITKFWPL-UHFFFAOYSA-N 4',5'-Dihydropsoralen Natural products C1=C2OC(=O)C=CC2=CC2=C1OCC2 VXGRJERITKFWPL-UHFFFAOYSA-N 0.000 description 1
QRXMUCSWCMTJGU-UHFFFAOYSA-N 5-bromo-4-chloro-3-indolyl phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP(O)(=O)O)=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-N 0.000 description 1
208000030507 AIDS Diseases 0.000 description 1
108010066676 Abrin Proteins 0.000 description 1
208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
102000011767 Acute-Phase Proteins Human genes 0.000 description 1
108010062271 Acute-Phase Proteins Proteins 0.000 description 1
208000009746 Adult T-Cell Leukemia-Lymphoma Diseases 0.000 description 1
208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
206010003267 Arthritis reactive Diseases 0.000 description 1
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
201000001320 Atherosclerosis Diseases 0.000 description 1
208000025324 B-cell acute lymphoblastic leukemia Diseases 0.000 description 1
208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
208000035143 Bacterial infection Diseases 0.000 description 1
208000023328 Basedow disease Diseases 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
101150111062 C gene Proteins 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
241000283707 Capra Species 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
206010008342 Cervix carcinoma Diseases 0.000 description 1
208000017667 Chronic Disease Diseases 0.000 description 1
208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
208000032544 Cicatrix Diseases 0.000 description 1
108020004705 Codon Proteins 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
206010009944 Colon cancer Diseases 0.000 description 1
108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
208000001333 Colorectal Neoplasms Diseases 0.000 description 1
MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
241000557626 Corvus corax Species 0.000 description 1
241000938605 Crocodylia Species 0.000 description 1
208000011231 Crohn disease Diseases 0.000 description 1
102100021906 Cyclin-O Human genes 0.000 description 1
UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 1
238000001712 DNA sequencing Methods 0.000 description 1
WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
241000702421 Dependoparvovirus Species 0.000 description 1
201000004624 Dermatitis Diseases 0.000 description 1
206010012438 Dermatitis atopic Diseases 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
102000016607 Diphtheria Toxin Human genes 0.000 description 1
108010053187 Diphtheria Toxin Proteins 0.000 description 1
208000006926 Discoid Lupus Erythematosus Diseases 0.000 description 1
101100102624 Drosophila melanogaster Vinc gene Proteins 0.000 description 1
238000012286 ELISA Assay Methods 0.000 description 1
LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
MBYXEBXZARTUSS-QLWBXOBMSA-N Emetamine Natural products O(C)c1c(OC)cc2c(c(C[C@@H]3[C@H](CC)CN4[C@H](c5c(cc(OC)c(OC)c5)CC4)C3)ncc2)c1 MBYXEBXZARTUSS-QLWBXOBMSA-N 0.000 description 1
201000009273 Endometriosis Diseases 0.000 description 1
241000620209 Escherichia coli DH5[alpha] Species 0.000 description 1
241000701959 Escherichia virus Lambda Species 0.000 description 1
208000006168 Ewing Sarcoma Diseases 0.000 description 1
238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
101150074355 GS gene Proteins 0.000 description 1
108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
208000007465 Giant cell arteritis Diseases 0.000 description 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
244000068988 Glycine max Species 0.000 description 1
235000010469 Glycine max Nutrition 0.000 description 1
108010026389 Gramicidin Proteins 0.000 description 1
102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
102100030385 Granzyme B Human genes 0.000 description 1
208000015023 Graves' disease Diseases 0.000 description 1
208000031886 HIV Infections Diseases 0.000 description 1
208000037357 HIV infectious disease Diseases 0.000 description 1
208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
206010019772 Hepatitis fulminant Diseases 0.000 description 1
101100297420 Homarus americanus phc-1 gene Proteins 0.000 description 1
101000897441 Homo sapiens Cyclin-O Proteins 0.000 description 1
101001009603 Homo sapiens Granzyme B Proteins 0.000 description 1
101000574992 Homo sapiens Mediator of RNA polymerase II transcription subunit 26 Proteins 0.000 description 1
101000617830 Homo sapiens Sterol O-acyltransferase 1 Proteins 0.000 description 1
101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
102000009490 IgG Receptors Human genes 0.000 description 1
108010073807 IgG Receptors Proteins 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
102000013463 Immunoglobulin Light Chains Human genes 0.000 description 1
108700015690 Immunoglobulin Switch Region Proteins 0.000 description 1
102100034343 Integrase Human genes 0.000 description 1
102000008070 Interferon-gamma Human genes 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
102000000589 Interleukin-1 Human genes 0.000 description 1
108010002352 Interleukin-1 Proteins 0.000 description 1
102000019223 Interleukin-1 receptor Human genes 0.000 description 1
108050006617 Interleukin-1 receptor Proteins 0.000 description 1
102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 description 1
102000000704 Interleukin-7 Human genes 0.000 description 1
102000004890 Interleukin-8 Human genes 0.000 description 1
108091092195 Intron Proteins 0.000 description 1
206010023203 Joint destruction Diseases 0.000 description 1
206010023232 Joint swelling Diseases 0.000 description 1
101150042441 K gene Proteins 0.000 description 1
238000012449 Kunming mouse Methods 0.000 description 1
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
206010023791 Large granular lymphocytosis Diseases 0.000 description 1
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
208000005777 Lupus Nephritis Diseases 0.000 description 1
208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
102000008072 Lymphokines Human genes 0.000 description 1
108010074338 Lymphokines Proteins 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
102100025546 Mediator of RNA polymerase II transcription subunit 26 Human genes 0.000 description 1
VFKZTMPDYBFSTM-KVTDHHQDSA-N Mitobronitol Chemical compound BrC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-KVTDHHQDSA-N 0.000 description 1
229930192392 Mitomycin Natural products 0.000 description 1
208000034578 Multiple myelomas Diseases 0.000 description 1
101100370002 Mus musculus Tnfsf14 gene Proteins 0.000 description 1
208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
206010028570 Myelopathy Diseases 0.000 description 1
OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
206010028811 Natural killer-cell leukaemia Diseases 0.000 description 1
208000005289 Neoplastic Cell Transformation Diseases 0.000 description 1
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
239000000020 Nitrocellulose Substances 0.000 description 1
208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
108700026244 Open Reading Frames Proteins 0.000 description 1
229930012538 Paclitaxel Natural products 0.000 description 1
229930040373 Paraformaldehyde Natural products 0.000 description 1
241001494479 Pecora Species 0.000 description 1
102000011755 Phosphoglycerate Kinase Human genes 0.000 description 1
102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
208000007452 Plasmacytoma Diseases 0.000 description 1
241000276498 Pollachius virens Species 0.000 description 1
229920002732 Polyanhydride Polymers 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
229920000954 Polyglycolide Polymers 0.000 description 1
229920001710 Polyorthoester Polymers 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
208000009052 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
108010029485 Protein Isoforms Proteins 0.000 description 1
102000001708 Protein Isoforms Human genes 0.000 description 1
206010037075 Protozoal infections Diseases 0.000 description 1
108091008109 Pseudogenes Proteins 0.000 description 1
102000057361 Pseudogenes Human genes 0.000 description 1
101000762949 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) Exotoxin A Proteins 0.000 description 1
201000001263 Psoriatic Arthritis Diseases 0.000 description 1
208000036824 Psoriatic arthropathy Diseases 0.000 description 1
108020005067 RNA Splice Sites Proteins 0.000 description 1
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
102000018120 Recombinases Human genes 0.000 description 1
108010091086 Recombinases Proteins 0.000 description 1
208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
108010039491 Ricin Proteins 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
AUVVAXYIELKVAI-UHFFFAOYSA-N SJ000285215 Natural products N1CCC2=CC(OC)=C(OC)C=C2C1CC1CC2C3=CC(OC)=C(OC)C=C3CCN2CC1CC AUVVAXYIELKVAI-UHFFFAOYSA-N 0.000 description 1
229920002684 Sepharose Polymers 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
208000009359 Sezary Syndrome Diseases 0.000 description 1
208000021388 Sezary disease Diseases 0.000 description 1
201000004283 Shwachman-Diamond syndrome Diseases 0.000 description 1
241000700584 Simplexvirus Species 0.000 description 1
208000006981 Skin Abnormalities Diseases 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
108010088160 Staphylococcal Protein A Proteins 0.000 description 1
102100021993 Sterol O-acyltransferase 1 Human genes 0.000 description 1
108010090804 Streptavidin Proteins 0.000 description 1
101000697584 Streptomyces lavendulae Streptothricin acetyltransferase Proteins 0.000 description 1
ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
238000000692 Student's t-test Methods 0.000 description 1
230000006043 T cell recruitment Effects 0.000 description 1
208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 1
208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 description 1
201000008717 T-cell large granular lymphocyte leukemia Diseases 0.000 description 1
208000000389 T-cell leukemia Diseases 0.000 description 1
208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 1
206010042971 T-cell lymphoma Diseases 0.000 description 1
208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
101150003725 TK gene Proteins 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
101001099217 Thermotoga maritima (strain ATCC 43589 / DSM 3109 / JCM 10099 / NBRC 100826 / MSB8) Triosephosphate isomerase Proteins 0.000 description 1
102000006601 Thymidine Kinase Human genes 0.000 description 1
108020004440 Thymidine kinase Proteins 0.000 description 1
206010044696 Tropical spastic paresis Diseases 0.000 description 1
GBOGMAARMMDZGR-UHFFFAOYSA-N UNPD149280 Natural products N1C(=O)C23OC(=O)C=CC(O)CCCC(C)CC=CC3C(O)C(=C)C(C)C2C1CC1=CC=CC=C1 GBOGMAARMMDZGR-UHFFFAOYSA-N 0.000 description 1
208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
206010046851 Uveitis Diseases 0.000 description 1
241000251539 Vertebrata <Metazoa> Species 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
239000003070 absorption delaying agent Substances 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
230000035508 accumulation Effects 0.000 description 1
229960001138 acetylsalicylic acid Drugs 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
229930183665 actinomycin Natural products 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
239000012072 active phase Substances 0.000 description 1
239000013543 active substance Substances 0.000 description 1
229960002964 adalimumab Drugs 0.000 description 1
201000006966 adult T-cell leukemia Diseases 0.000 description 1
201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
229940013181 advil Drugs 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
238000000246 agarose gel electrophoresis Methods 0.000 description 1
208000015230 aggressive NK-cell leukemia Diseases 0.000 description 1
239000000556 agonist Substances 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
239000003513 alkali Substances 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
150000001342 alkaline earth metals Chemical class 0.000 description 1
229940100198 alkylating agent Drugs 0.000 description 1
239000002168 alkylating agent Substances 0.000 description 1
FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
230000007815 allergy Effects 0.000 description 1
239000002160 alpha blocker Substances 0.000 description 1
229940087168 alpha tocopherol Drugs 0.000 description 1
229940124308 alpha-adrenoreceptor antagonist Drugs 0.000 description 1
230000004075 alteration Effects 0.000 description 1
230000001668 ameliorated effect Effects 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
229960004238 anakinra Drugs 0.000 description 1
238000010171 animal model Methods 0.000 description 1
229940045799 anthracyclines and related substance Drugs 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
230000000340 anti-metabolite Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
238000011091 antibody purification Methods 0.000 description 1
238000011230 antibody-based therapy Methods 0.000 description 1
229940033495 antimalarials Drugs 0.000 description 1
229940100197 antimetabolite Drugs 0.000 description 1
239000002256 antimetabolite Substances 0.000 description 1
239000003080 antimitotic agent Substances 0.000 description 1
239000012062 aqueous buffer Substances 0.000 description 1
239000008365 aqueous carrier Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
229940059756 arava Drugs 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
238000000149 argon plasma sintering Methods 0.000 description 1
159000000032 aromatic acids Chemical class 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
235000010385 ascorbyl palmitate Nutrition 0.000 description 1
235000009582 asparagine Nutrition 0.000 description 1
229960001230 asparagine Drugs 0.000 description 1
235000003704 aspartic acid Nutrition 0.000 description 1
201000008937 atopic dermatitis Diseases 0.000 description 1
208000022362 bacterial infectious disease Diseases 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
229920000249 biocompatible polymer Polymers 0.000 description 1
229920002988 biodegradable polymer Polymers 0.000 description 1
230000008436 biogenesis Effects 0.000 description 1
230000008033 biological extinction Effects 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
230000008512 biological response Effects 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
RSIHSRDYCUFFLA-DYKIIFRCSA-N boldenone Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 RSIHSRDYCUFFLA-DYKIIFRCSA-N 0.000 description 1
210000001185 bone marrow Anatomy 0.000 description 1
238000009395 breeding Methods 0.000 description 1
230000001488 breeding effect Effects 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
239000007975 buffered saline Substances 0.000 description 1
229960002092 busulfan Drugs 0.000 description 1
DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000011575 calcium Substances 0.000 description 1
239000002775 capsule Substances 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
239000005018 casein Substances 0.000 description 1
BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
235000021240 caseins Nutrition 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
229940047495 celebrex Drugs 0.000 description 1
229960000590 celecoxib Drugs 0.000 description 1
230000022131 cell cycle Effects 0.000 description 1
230000011712 cell development Effects 0.000 description 1
230000003915 cell function Effects 0.000 description 1
230000004709 cell invasion Effects 0.000 description 1
239000013592 cell lysate Substances 0.000 description 1
230000011748 cell maturation Effects 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
238000001516 cell proliferation assay Methods 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
208000011235 central nervous system lupus Diseases 0.000 description 1
201000010881 cervical cancer Diseases 0.000 description 1
239000002738 chelating agent Substances 0.000 description 1
NDAYQJDHGXTBJL-MWWSRJDJSA-N chembl557217 Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](NC(=O)CNC(=O)[C@@H](NC=O)C(C)C)CC(C)C)C(=O)NCCO)=CNC2=C1 NDAYQJDHGXTBJL-MWWSRJDJSA-N 0.000 description 1
229940044683 chemotherapy drug Drugs 0.000 description 1
229960004630 chlorambucil Drugs 0.000 description 1
229960004926 chlorobutanol Drugs 0.000 description 1
VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
229960002023 chloroprocaine Drugs 0.000 description 1
OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
229960001231 choline Drugs 0.000 description 1
239000013611 chromosomal DNA Substances 0.000 description 1
208000037976 chronic inflammation Diseases 0.000 description 1
208000037893 chronic inflammatory disorder Diseases 0.000 description 1
208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
238000011260 co-administration Methods 0.000 description 1
239000011280 coal tar Substances 0.000 description 1
229960001338 colchicine Drugs 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
230000004154 complement system Effects 0.000 description 1
230000000536 complexating effect Effects 0.000 description 1
238000013329 compounding Methods 0.000 description 1
210000002808 connective tissue Anatomy 0.000 description 1
238000010276 construction Methods 0.000 description 1
239000000356 contaminant Substances 0.000 description 1
239000013068 control sample Substances 0.000 description 1
239000000599 controlled substance Substances 0.000 description 1
230000006003 cornification Effects 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
229960004544 cortisone Drugs 0.000 description 1
229940111134 coxibs Drugs 0.000 description 1
201000007241 cutaneous T cell lymphoma Diseases 0.000 description 1
208000004921 cutaneous lupus erythematosus Diseases 0.000 description 1
208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
230000001351 cycling effect Effects 0.000 description 1
239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
229960002433 cysteine Drugs 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
229960001305 cysteine hydrochloride Drugs 0.000 description 1
229960003067 cystine Drugs 0.000 description 1
229960000684 cytarabine Drugs 0.000 description 1
GBOGMAARMMDZGR-TYHYBEHESA-N cytochalasin B Chemical compound C([C@H]1[C@@H]2[C@@H](C([C@@H](O)[C@@H]3/C=C/C[C@H](C)CCC[C@@H](O)/C=C/C(=O)O[C@@]23C(=O)N1)=C)C)C1=CC=CC=C1 GBOGMAARMMDZGR-TYHYBEHESA-N 0.000 description 1
GBOGMAARMMDZGR-JREHFAHYSA-N cytochalasin B Natural products C[C@H]1CCC[C@@H](O)C=CC(=O)O[C@@]23[C@H](C=CC1)[C@H](O)C(=C)[C@@H](C)[C@@H]2[C@H](Cc4ccccc4)NC3=O GBOGMAARMMDZGR-JREHFAHYSA-N 0.000 description 1
230000000093 cytochemical effect Effects 0.000 description 1
210000000805 cytoplasm Anatomy 0.000 description 1
238000012303 cytoplasmic staining Methods 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
229940070230 daypro Drugs 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
RSIHSRDYCUFFLA-UHFFFAOYSA-N dehydrotestosterone Natural products O=C1C=CC2(C)C3CCC(C)(C(CC4)O)C4C3CCC2=C1 RSIHSRDYCUFFLA-UHFFFAOYSA-N 0.000 description 1
201000001981 dermatomyositis Diseases 0.000 description 1
230000001066 destructive effect Effects 0.000 description 1
230000001627 detrimental effect Effects 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
150000001991 dicarboxylic acids Chemical class 0.000 description 1
229960001259 diclofenac Drugs 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
229940043237 diethanolamine Drugs 0.000 description 1
229960000616 diflunisal Drugs 0.000 description 1
238000007865 diluting Methods 0.000 description 1
230000009266 disease activity Effects 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
238000009826 distribution Methods 0.000 description 1
229940072701 dolobid Drugs 0.000 description 1
230000002222 downregulating effect Effects 0.000 description 1
230000000431 effect on proliferation Effects 0.000 description 1
239000012636 effector Substances 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
AUVVAXYIELKVAI-CKBKHPSWSA-N emetine Chemical compound N1CCC2=CC(OC)=C(OC)C=C2[C@H]1C[C@H]1C[C@H]2C3=CC(OC)=C(OC)C=C3CCN2C[C@@H]1CC AUVVAXYIELKVAI-CKBKHPSWSA-N 0.000 description 1
229960002694 emetine Drugs 0.000 description 1
AUVVAXYIELKVAI-UWBTVBNJSA-N emetine Natural products N1CCC2=CC(OC)=C(OC)C=C2[C@H]1C[C@H]1C[C@H]2C3=CC(OC)=C(OC)C=C3CCN2C[C@H]1CC AUVVAXYIELKVAI-UWBTVBNJSA-N 0.000 description 1
229940073621 enbrel Drugs 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
210000002615 epidermis Anatomy 0.000 description 1
210000002919 epithelial cell Anatomy 0.000 description 1
210000003238 esophagus Anatomy 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
229960005542 ethidium bromide Drugs 0.000 description 1
LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
229940093471 ethyl oleate Drugs 0.000 description 1
239000005038 ethylene vinyl acetate Substances 0.000 description 1
229940012017 ethylenediamine Drugs 0.000 description 1
VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
229960005420 etoposide Drugs 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
239000013613 expression plasmid Substances 0.000 description 1
238000000605 extraction Methods 0.000 description 1
210000003414 extremity Anatomy 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
RDJGLLICXDHJDY-UHFFFAOYSA-N fenoprofen Chemical compound OC(=O)C(C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-UHFFFAOYSA-N 0.000 description 1
229960001419 fenoprofen Drugs 0.000 description 1
230000001605 fetal effect Effects 0.000 description 1
230000003176 fibrotic effect Effects 0.000 description 1
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
229960002949 fluorouracil Drugs 0.000 description 1
239000006260 foam Substances 0.000 description 1
229960000304 folic acid Drugs 0.000 description 1
235000019152 folic acid Nutrition 0.000 description 1
239000011724 folic acid Substances 0.000 description 1
230000005714 functional activity Effects 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
238000001502 gel electrophoresis Methods 0.000 description 1
238000012637 gene transfection Methods 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
238000003205 genotyping method Methods 0.000 description 1
229940084910 gliadel Drugs 0.000 description 1
239000003862 glucocorticoid Substances 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
150000002343 gold Chemical class 0.000 description 1
239000008187 granular material Substances 0.000 description 1
210000004013 groin Anatomy 0.000 description 1
230000009036 growth inhibition Effects 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
229940093915 gynecological organic acid Drugs 0.000 description 1
238000003306 harvesting Methods 0.000 description 1
230000036541 health Effects 0.000 description 1
208000025750 heavy chain disease Diseases 0.000 description 1
210000002443 helper t lymphocyte Anatomy 0.000 description 1
230000011132 hemopoiesis Effects 0.000 description 1
102000057041 human TNF Human genes 0.000 description 1
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
229940071870 hydroiodic acid Drugs 0.000 description 1
150000002433 hydrophilic molecules Chemical class 0.000 description 1
229960004171 hydroxychloroquine Drugs 0.000 description 1
230000001969 hypertrophic effect Effects 0.000 description 1
229960001680 ibuprofen Drugs 0.000 description 1
230000002519 immonomodulatory effect Effects 0.000 description 1
230000016784 immunoglobulin production Effects 0.000 description 1
230000002055 immunohistochemical effect Effects 0.000 description 1
238000011532 immunohistochemical staining Methods 0.000 description 1
238000003364 immunohistochemistry Methods 0.000 description 1
239000000367 immunologic factor Substances 0.000 description 1
239000012073 inactive phase Substances 0.000 description 1
229940089536 indocin Drugs 0.000 description 1
CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 1
239000003701 inert diluent Substances 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
210000004969 inflammatory cell Anatomy 0.000 description 1
230000004968 inflammatory condition Effects 0.000 description 1
208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
229960003130 interferon gamma Drugs 0.000 description 1
229940047124 interferons Drugs 0.000 description 1
229940100601 interleukin-6 Drugs 0.000 description 1
108040006858 interleukin-6 receptor activity proteins Proteins 0.000 description 1
230000016507 interphase Effects 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
238000001361 intraarterial administration Methods 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
210000005024 intraepithelial lymphocyte Anatomy 0.000 description 1
XMBWDFGMSWQBCA-RNFDNDRNSA-M iodine-131(1-) Chemical compound [131I-] XMBWDFGMSWQBCA-RNFDNDRNSA-M 0.000 description 1
210000004153 islets of langerhan Anatomy 0.000 description 1
229960000991 ketoprofen Drugs 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
229940054136 kineret Drugs 0.000 description 1
238000012933 kinetic analysis Methods 0.000 description 1
208000037393 large granular lymphocyte leukemia Diseases 0.000 description 1
239000010410 layer Substances 0.000 description 1
230000003902 lesion Effects 0.000 description 1
229940063725 leukeran Drugs 0.000 description 1
229960004194 lidocaine Drugs 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
230000005817 liver abnormality Effects 0.000 description 1
229960002247 lomustine Drugs 0.000 description 1
230000007774 longterm Effects 0.000 description 1
239000006210 lotion Substances 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
230000005823 lung abnormality Effects 0.000 description 1
201000011649 lymphoblastic lymphoma Diseases 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
238000002794 lymphocyte assay Methods 0.000 description 1
230000000527 lymphocytic effect Effects 0.000 description 1
239000006166 lysate Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
210000001161 mammalian embryo Anatomy 0.000 description 1
150000008146 mannosides Chemical class 0.000 description 1
239000003550 marker Substances 0.000 description 1
230000013011 mating Effects 0.000 description 1
238000005259 measurement Methods 0.000 description 1
229960004961 mechlorethamine Drugs 0.000 description 1
HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
201000001441 melanoma Diseases 0.000 description 1
SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
229960001924 melphalan Drugs 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
239000004530 micro-emulsion Substances 0.000 description 1
238000001471 micro-filtration Methods 0.000 description 1
206010063344 microscopic polyangiitis Diseases 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
229960005485 mitobronitol Drugs 0.000 description 1
230000000394 mitotic effect Effects 0.000 description 1
229960001156 mitoxantrone Drugs 0.000 description 1
KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
230000001483 mobilizing effect Effects 0.000 description 1
239000000178 monomer Substances 0.000 description 1
229940072709 motrin Drugs 0.000 description 1
210000004400 mucous membrane Anatomy 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
206010028417 myasthenia gravis Diseases 0.000 description 1
229960004270 nabumetone Drugs 0.000 description 1
229940089466 nalfon Drugs 0.000 description 1
210000000822 natural killer cell Anatomy 0.000 description 1
239000013642 negative control Substances 0.000 description 1
230000000926 neurological effect Effects 0.000 description 1
210000000440 neutrophil Anatomy 0.000 description 1
229910017604 nitric acid Inorganic materials 0.000 description 1
229920001220 nitrocellulos Polymers 0.000 description 1
230000009871 nonspecific binding Effects 0.000 description 1
238000012758 nuclear staining Methods 0.000 description 1
230000000414 obstructive effect Effects 0.000 description 1
239000002674 ointment Substances 0.000 description 1
238000002515 oligonucleotide synthesis Methods 0.000 description 1
235000008390 olive oil Nutrition 0.000 description 1
239000004006 olive oil Substances 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
238000005457 optimization Methods 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
150000002895 organic esters Chemical class 0.000 description 1
201000008482 osteoarthritis Diseases 0.000 description 1
230000001151 other effect Effects 0.000 description 1
235000006408 oxalic acid Nutrition 0.000 description 1
229960002739 oxaprozin Drugs 0.000 description 1
239000007800 oxidant agent Substances 0.000 description 1
229960001592 paclitaxel Drugs 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
229920002866 paraformaldehyde Polymers 0.000 description 1
230000037361 pathway Effects 0.000 description 1
239000008188 pellet Substances 0.000 description 1
230000035699 permeability Effects 0.000 description 1
238000002823 phage display Methods 0.000 description 1
QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
210000002826 placenta Anatomy 0.000 description 1
229940072689 plaquenil Drugs 0.000 description 1
239000013600 plasmid vector Substances 0.000 description 1
229940063179 platinol Drugs 0.000 description 1
229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
229920000747 poly(lactic acid) Polymers 0.000 description 1
239000004633 polyglycolic acid Substances 0.000 description 1
239000004626 polylactic acid Substances 0.000 description 1
208000005987 polymyositis Diseases 0.000 description 1
108091033319 polynucleotide Proteins 0.000 description 1
102000040430 polynucleotide Human genes 0.000 description 1
239000002157 polynucleotide Substances 0.000 description 1
230000002980 postoperative effect Effects 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
210000001948 pro-b lymphocyte Anatomy 0.000 description 1
238000012545 processing Methods 0.000 description 1
230000000644 propagated effect Effects 0.000 description 1
230000001902 propagating effect Effects 0.000 description 1
239000003380 propellant Substances 0.000 description 1
229960003712 propranolol Drugs 0.000 description 1
239000000473 propyl gallate Substances 0.000 description 1
235000010388 propyl gallate Nutrition 0.000 description 1
229940075579 propyl gallate Drugs 0.000 description 1
238000000159 protein binding assay Methods 0.000 description 1
230000006916 protein interaction Effects 0.000 description 1
230000005892 protein maturation Effects 0.000 description 1
238000003906 pulsed field gel electrophoresis Methods 0.000 description 1
229950010131 puromycin Drugs 0.000 description 1
230000006824 pyrimidine synthesis Effects 0.000 description 1
238000011002 quantification Methods 0.000 description 1
239000001397 quillaja saponaria molina bark Substances 0.000 description 1
239000012217 radiopharmaceutical Substances 0.000 description 1
229940121896 radiopharmaceutical Drugs 0.000 description 1
230000002799 radiopharmaceutical effect Effects 0.000 description 1
206010037844 rash Diseases 0.000 description 1
208000002574 reactive arthritis Diseases 0.000 description 1
230000009467 reduction Effects 0.000 description 1
239000013643 reference control Substances 0.000 description 1
230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
229940087462 relafen Drugs 0.000 description 1
229940116176 remicade Drugs 0.000 description 1
230000008521 reorganization Effects 0.000 description 1
230000003252 repetitive effect Effects 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
210000001995 reticulocyte Anatomy 0.000 description 1
238000012552 review Methods 0.000 description 1
201000009410 rhabdomyosarcoma Diseases 0.000 description 1
229940061969 rheumatrex Drugs 0.000 description 1
RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 1
150000003873 salicylate salts Chemical class 0.000 description 1
229930182490 saponin Natural products 0.000 description 1
150000007949 saponins Chemical class 0.000 description 1
230000037387 scars Effects 0.000 description 1
230000003248 secreting effect Effects 0.000 description 1
230000028327 secretion Effects 0.000 description 1
238000002741 site-directed mutagenesis Methods 0.000 description 1
201000010153 skin papilloma Diseases 0.000 description 1
210000000813 small intestine Anatomy 0.000 description 1
150000003384 small molecules Chemical class 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
229910000342 sodium bisulfate Inorganic materials 0.000 description 1
229940100996 sodium bisulfate Drugs 0.000 description 1
CSMWJXBSXGUPGY-UHFFFAOYSA-L sodium dithionate Chemical compound [Na+].[Na+].[O-]S(=O)(=O)S([O-])(=O)=O CSMWJXBSXGUPGY-UHFFFAOYSA-L 0.000 description 1
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
229940054269 sodium pyruvate Drugs 0.000 description 1
235000010265 sodium sulphite Nutrition 0.000 description 1
235000010199 sorbic acid Nutrition 0.000 description 1
239000004334 sorbic acid Substances 0.000 description 1
229940075582 sorbic acid Drugs 0.000 description 1
238000002798 spectrophotometry method Methods 0.000 description 1
210000004989 spleen cell Anatomy 0.000 description 1
210000000130 stem cell Anatomy 0.000 description 1
239000008221 sterile excipient Substances 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
229960001052 streptozocin Drugs 0.000 description 1
ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 1
229960000894 sulindac Drugs 0.000 description 1
230000036561 sun exposure Effects 0.000 description 1
230000008093 supporting effect Effects 0.000 description 1
108010033090 surfactant protein A receptor Proteins 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
230000002195 synergetic effect Effects 0.000 description 1
229940037128 systemic glucocorticoids Drugs 0.000 description 1
239000003826 tablet Substances 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
206010043207 temporal arteritis Diseases 0.000 description 1
NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
229960001278 teniposide Drugs 0.000 description 1
229960002372 tetracaine Drugs 0.000 description 1
GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 description 1
238000010257 thawing Methods 0.000 description 1
230000008719 thickening Effects 0.000 description 1
239000003104 tissue culture media Substances 0.000 description 1
AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 1
229960000984 tocofersolan Drugs 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
210000003437 trachea Anatomy 0.000 description 1
230000005030 transcription termination Effects 0.000 description 1
230000002103 transcriptional effect Effects 0.000 description 1
238000012546 transfer Methods 0.000 description 1
230000009466 transformation Effects 0.000 description 1
230000032258 transport Effects 0.000 description 1
208000006961 tropical spastic paraparesis Diseases 0.000 description 1
230000004614 tumor growth Effects 0.000 description 1
210000003954 umbilical cord Anatomy 0.000 description 1
241000701161 unidentified adenovirus Species 0.000 description 1
241001430294 unidentified retrovirus Species 0.000 description 1
210000004291 uterus Anatomy 0.000 description 1
238000001291 vacuum drying Methods 0.000 description 1
230000006496 vascular abnormality Effects 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
229960004528 vincristine Drugs 0.000 description 1
238000012800 visualization Methods 0.000 description 1
235000019155 vitamin A Nutrition 0.000 description 1
239000011719 vitamin A Substances 0.000 description 1
229940045997 vitamin a Drugs 0.000 description 1
229940063674 voltaren Drugs 0.000 description 1
238000003260 vortexing Methods 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1
238000001262 western blot Methods 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
210000005253 yeast cell Anatomy 0.000 description 1
239000002076 α-tocopherol Substances 0.000 description 1
235000004835 α-tocopherol Nutrition 0.000 description 1
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1

Images

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

JP2006502466A 2003-02-26 2004-02-25 インターロイキン１５（ｉｌ−１５）に特異的なヒト抗体 Expired - Lifetime JP4892335B2 (ja)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US10/374,932 US7329405B2 (en)	2001-08-23	2003-02-26	Human antibodies specific for interleukin 15 (IL-15)
US10/374,932		2003-02-26
US10/379,741		2003-03-05
US10/379,741 US7247304B2 (en)	2001-08-23	2003-03-05	Methods of treating using anti-IL-15 antibodies
PCT/IB2004/000484 WO2004076620A2 (en)	2003-02-26	2004-02-25	Human antibodies specific for interleukin 15 (il-15)

Publications (2)

Publication Number	Publication Date
JP2007528348A JP2007528348A (ja)	2007-10-11
JP4892335B2 true JP4892335B2 (ja)	2012-03-07

Family

ID=36770634

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2006502466A Expired - Lifetime JP4892335B2 (ja)	2003-02-26	2004-02-25	インターロイキン１５（ｉｌ−１５）に特異的なヒト抗体

Country Status (6)

Country	Link
JP (1)	JP4892335B2 (es)
CN (1)	CN1780856A (es)
AR (1)	AR043405A1 (es)
EA (1)	EA015897B1 (es)
RS (1)	RS20050724A (es)
ZA (1)	ZA200506724B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2690825C (en)	2007-05-11	2019-02-12	Altor Bioscience Corporation	Fusion molecules and il-15 variants
US11053299B2 (en)	2010-09-21	2021-07-06	Immunity Bio, Inc.	Superkine
KR20140020228A (ko)	2010-09-21	2014-02-18	알토 바이오사이언스 코포레이션	다량체성 아이엘 15 용해성 융합 분자 및 그의 제조 및 사용 방법
CN102250243B (zh) *	2011-07-01	2013-08-28	华绍炳	抗白细胞介素-15抗体
US9925247B2 (en)	2014-06-30	2018-03-27	Altor Bioscience Corporation	IL-15-based molecules and methods of use thereof
EP2963057A1 (en) *	2014-07-02	2016-01-06	Calypso Biotech SA	Antibodies to IL-15
BR112018076287A2 (pt) *	2016-06-15	2019-03-26	Amgen Inc.	métodos e composições para o tratamento de doença celíaca, sensibilidade ao glúten não celíaca e doença celíaca refratária
SG11201903306SA (en)	2016-10-21	2019-05-30	Altor Bioscience Corp	Multimeric il-15-based molecules
AR110414A1 (es) *	2016-12-21	2019-03-27	Cephalon Inc	Anticuerpos que se unen específicamente a il-15 humana y usos de estos
US20220354097A1 (en) *	2019-12-25	2022-11-10	Gempharmatech Co., Ltd.	Il-15 humanized mouse model and use thereof
CN114377133A (zh) *	2022-01-20	2022-04-22	山东大学	靶向肾脏cd8+trm形成与活化在肾小球损伤中的应用
CN115362984B (zh) *	2022-07-07	2024-01-16	成都中医药大学	一种小鼠自身免疫性甲状腺炎模型的构建方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2001002003A1 (en) *	1999-07-06	2001-01-11	Bulfone Paus Silvia	Method of treating psoriasis with il-15 antagonist
JP2002520294A (ja) *	1998-07-10	2002-07-09	ザマティルダアンドテレンスケネディインスティチュートオブリューマトロジー	インターロイキン−１５拮抗薬によるセリアック病の治療
JP4359503B2 (ja) *	2001-08-23	2009-11-04	ゲンマブエー／エス	インターロイキン１５（ｉｌ−１５）に特異的なヒト抗体

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5795966A (en) *	1995-02-22	1998-08-18	Immunex Corp	Antagonists of interleukin-15

2004
- 2004-02-25 ZA ZA200506724A patent/ZA200506724B/en unknown
- 2004-02-25 RS YUP-2005/0724A patent/RS20050724A/sr unknown
- 2004-02-25 EA EA200501362A patent/EA015897B1/ru not_active IP Right Cessation
- 2004-02-25 CN CN 200480011288 patent/CN1780856A/zh active Pending
- 2004-02-25 JP JP2006502466A patent/JP4892335B2/ja not_active Expired - Lifetime
- 2004-02-26 AR ARP040100605 patent/AR043405A1/es not_active Application Discontinuation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2002520294A (ja) *	1998-07-10	2002-07-09	ザマティルダアンドテレンスケネディインスティチュートオブリューマトロジー	インターロイキン−１５拮抗薬によるセリアック病の治療
WO2001002003A1 (en) *	1999-07-06	2001-01-11	Bulfone Paus Silvia	Method of treating psoriasis with il-15 antagonist
JP4359503B2 (ja) *	2001-08-23	2009-11-04	ゲンマブエー／エス	インターロイキン１５（ｉｌ−１５）に特異的なヒト抗体

Also Published As

Publication number	Publication date
RS20050724A (en)	2007-11-15
EA015897B1 (ru)	2011-12-30
CN1780856A (zh)	2006-05-31
AR043405A1 (es)	2005-07-27
ZA200506724B (en)	2007-03-28
EA200501362A1 (ru)	2006-02-24
JP2007528348A (ja)	2007-10-11

Legal Events

Date	Code	Title	Description
2010-04-14	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100413
2010-07-14	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100713
2010-08-18	A02	Decision of refusal	Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100817
2010-12-18	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20101217
2011-02-25	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20110208
2011-03-03	A911	Transfer to examiner for re-examination before appeal (zenchi)	Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20110302
2011-04-27	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A132 Effective date: 20110426
2011-07-23	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110722
2011-09-27	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110927
2011-11-05	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20111104
2011-12-05	TRDD	Decision of grant or rejection written
2011-12-14	A01	Written decision to grant a patent or to grant a registration (utility model)	Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20111213
2011-12-15	A01	Written decision to grant a patent or to grant a registration (utility model)	Free format text: JAPANESE INTERMEDIATE CODE: A01
2011-12-22	A61	First payment of annual fees (during grant procedure)	Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20111219
2011-12-22	R150	Certificate of patent or registration of utility model	Ref document number: 4892335 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150
2011-12-26	FPAY	Renewal fee payment (event date is renewal date of database)	Free format text: PAYMENT UNTIL: 20141222 Year of fee payment: 3
2014-12-16	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2015-12-15	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2016-12-06	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2017-12-05	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2018-12-04	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2019-12-03	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2020-11-30	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2021-11-30	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2022-12-02	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2023-12-01	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250

Publication	Publication Date	Title
JP4359503B2 (ja)	2009-11-04	インターロイキン１５（ｉｌ−１５）に特異的なヒト抗体
US7247304B2 (en)	2007-07-24	Methods of treating using anti-IL-15 antibodies
AU2002332628A1 (en)	2003-06-05	Human antibodies specific for interleukin 15 (IL-15)
KR101329843B1 (ko)	2013-11-14	Ｃｄ25에 대한 인간 모노클로날 항체
JP4606172B2 (ja)	2011-01-05	上皮成長因子受容体（ｅｇｆｒ）に対するヒトモノクローナル抗体
JP4999158B2 (ja)	2012-08-15	炭疽菌（ｂａｃｈｉｌｌｕｓａｎｔｈｒａｃｉｓ）の感染防御抗原に対するヒトモノクローナル抗体
CN103709250B (zh)	2016-08-10	抗cd20的人单克隆抗体
JP4892335B2 (ja)	2012-03-07	インターロイキン１５（ｉｌ−１５）に特異的なヒト抗体
US7329405B2 (en)	2008-02-12	Human antibodies specific for interleukin 15 (IL-15)